BACKGROUND: The goal of HAART is to promote reconstitution of CD4+ T cells and other immune responses. We evaluated the extent and the kinetics of immune reconstitution in HIV-infected children over 144 weeks of successful HAART. METHODS: Thirty-seven children receiving their first HAART regimen had plasma HIV RNA; T cells and subpopulations; T-cell rearrangement excision circles (TREC) DNA; candida, HIVCD4 and HIVCD8 enzyme-linked immunospot measured at regular intervals. RESULTS: Plasma HIV RNA became undetectable in 81% of patients at 24 weeks and remained undetectable in 77% at 144 weeks. In contrast, CD4+% continuously increased. Distribution of T-cell subpopulations changed rapidly during the first 48 weeks of HAART and more slowly thereafter. At 144 weeks, total, naive and activated CD4+% and naive CD8+% of HIV-infected children were not significantly different from those of healthy age-matched controls, whereas total and activated CD8+% remained elevated. CD4 and CD8 TREC content increased only during the first 48 weeks of HAART. They positively correlated with each other and with total CD4+%, naive CD4+% and naive CD8+%. Candida and HIVCD4 enzyme-linked immunospot increased over time reaching peak values at 48 weeks and 144 weeks, respectively. HIVCD8 enzyme-linked immunospot decreased in magnitude over 144 weeks of HAART but retained its breadth. Baseline CD4+% positively correlated with CD4+% and with functional immune reconstitution at week 144, whereas baseline TREC correlated with TREC at week 144. CONCLUSION: HIV-infected children acquired normal distribution of CD4 T cells and other subpopulations and recovered CD4-mediated HIV immunity after 144 weeks of HAART.
BACKGROUND: The goal of HAART is to promote reconstitution of CD4+ T cells and other immune responses. We evaluated the extent and the kinetics of immune reconstitution in HIV-infectedchildren over 144 weeks of successful HAART. METHODS: Thirty-seven children receiving their first HAART regimen had plasma HIV RNA; T cells and subpopulations; T-cell rearrangement excision circles (TREC) DNA; candida, HIVCD4 and HIVCD8 enzyme-linked immunospot measured at regular intervals. RESULTS: Plasma HIV RNA became undetectable in 81% of patients at 24 weeks and remained undetectable in 77% at 144 weeks. In contrast, CD4+% continuously increased. Distribution of T-cell subpopulations changed rapidly during the first 48 weeks of HAART and more slowly thereafter. At 144 weeks, total, naive and activated CD4+% and naive CD8+% of HIV-infectedchildren were not significantly different from those of healthy age-matched controls, whereas total and activated CD8+% remained elevated. CD4 and CD8 TREC content increased only during the first 48 weeks of HAART. They positively correlated with each other and with total CD4+%, naive CD4+% and naive CD8+%. Candida and HIVCD4 enzyme-linked immunospot increased over time reaching peak values at 48 weeks and 144 weeks, respectively. HIVCD8 enzyme-linked immunospot decreased in magnitude over 144 weeks of HAART but retained its breadth. Baseline CD4+% positively correlated with CD4+% and with functional immune reconstitution at week 144, whereas baseline TREC correlated with TREC at week 144. CONCLUSION:HIV-infectedchildren acquired normal distribution of CD4 T cells and other subpopulations and recovered CD4-mediated HIV immunity after 144 weeks of HAART.
Authors: D C Douek; M R Betts; B J Hill; S J Little; R Lempicki; J A Metcalf; J Casazza; C Yoder; J W Adelsberger; R A Stevens; M W Baseler; P Keiser; D D Richman; R T Davey; R A Koup Journal: J Immunol Date: 2001-12-01 Impact factor: 5.422
Authors: S L Gortmaker; M Hughes; J Cervia; M Brady; G M Johnson; G R Seage; L Y Song; W M Dankner; J M Oleske Journal: N Engl J Med Date: 2001-11-22 Impact factor: 91.245
Authors: T C Greenough; D B Brettler; F Kirchhoff; L Alexander; R C Desrosiers; S J O'Brien; M Somasundaran; K Luzuriaga; J L Sullivan Journal: J Infect Dis Date: 1999-12 Impact factor: 5.226
Authors: M D Hazenberg; S A Otto; J W Cohen Stuart; M C Verschuren; J C Borleffs; C A Boucher; R A Coutinho; J M Lange; T F Rinke de Wit; A Tsegaye; J J van Dongen; D Hamann; R J de Boer; F Miedema Journal: Nat Med Date: 2000-09 Impact factor: 53.440
Authors: C Chougnet; S Jankelevich; K Fowke; D Liewehr; S M Steinberg; B U Mueller; P A Pizzo; R Yarchoan; G M Shearer Journal: J Infect Dis Date: 2001-06-08 Impact factor: 5.226
Authors: W Borkowsky; K Stanley; S D Douglas; S Lee; A Wiznia; S Pelton; R Yogev; K McIntosh; S Nachman Journal: J Infect Dis Date: 2000-06-27 Impact factor: 5.226
Authors: A Mocroft; A N Phillips; J Gatell; B Ledergerber; M Fisher; N Clumeck; M Losso; A Lazzarin; G Fatkenheuer; J D Lundgren Journal: Lancet Date: 2007-08-04 Impact factor: 79.321
Authors: Adriana Weinberg; Lin Ye Song; Cindy L Wilkening; Terry Fenton; John Hural; Raul Louzao; Guido Ferrari; Paige E Etter; Mark Berrong; Jennifer D Canniff; Donald Carter; Olivier D Defawe; Ambrosia Garcia; Tania L Garrelts; Rebecca Gelman; Linda K Lambrecht; Savita Pahwa; Sudheesh Pilakka-Kanthikeel; David L Shugarts; Nancy B Tustin Journal: J Immunol Methods Date: 2010-10-01 Impact factor: 2.303
Authors: Russell B Van Dyke; Kunjal Patel; George K Siberry; Sandra K Burchett; Stephen A Spector; Miriam C Chernoff; Jennifer S Read; Lynne M Mofenson; George R Seage Journal: J Acquir Immune Defic Syndr Date: 2011-06-01 Impact factor: 3.731
Authors: Dwight E Yin; Meredith G Warshaw; William C Miller; Hannah Castro; Susan A Fiscus; Lynda M Harper; Linda J Harrison; Nigel J Klein; Joanna Lewis; Ann J Melvin; Gareth Tudor-Williams; Ross E McKinney Journal: Pediatrics Date: 2014-10 Impact factor: 7.124
Authors: Myron J Levin; Jeffrey P Anderson; George R Seage; Paige L Williams Journal: J Acquir Immune Defic Syndr Date: 2009-02-01 Impact factor: 3.731